OBJECTIVE:
Vaginal pessaries are a treatment for gravid patients with short cervix. Increased discharge has been a consistent finding in multiple prior investigations and it's etiology has not been elucidated. We aimed to explore variation in cytokine expression following placement of a vaginal pessary in patients with short funneled cervix. We hypothesize that the cytokine expression profile is altered as a consequence of pessary use. STUDY DESIGN: This is a prospective cohort study of patients who received Milex Ò Inflatoball pessaries for shortened cervix. Gestational age-matched controls without cervical shortening served as the control group. Following consent, pessary and control patients underwent collection of sterile vaginal lavage for baseline specimen. Both arms were followed longitudinally and underwent vaginal lavage collection a week later and then monthly. Multiplexed ELISA analyzed 38 cytokines with a broad survey panel. Cytokine levels were compared longitudinally within each arm, between baseline experimental subjects and controls and longitudinal cytokine concentration was compared between the two arms. Pair-wise comparisons were performed using Mann-Whitney U test. RESULTS: Most of the 38 cytokines were below the level of detection. Granulocyte-colony stimulating factor (G-CSF) demonstrated significant differences between pre-and post-pessary arm and post-pessary arm (p<.0001) and baseline pessary arm and baseline control arm (p¼.0003). Interleukin-4 (IL-4) likewise was significantly different between baseline specimens in each arm (p¼.003) and pre-and post-pessary arms (<.0001). Interleukin-6 was expressed differently in pre-and post-pessary arms (p<.0001), baseline pessary and baseline control arms (p¼.0101), and longitudinal pessary and control arms (p<.0001). Interleukin-1-a (IL-1-a) was variably expressed between baseline arms (p<.0001). CONCLUSION: Significant variation in cytokine expression of G-CSF, IL-4, IL-6, and IL-1-a was noted in pessary patients compared with controls. Reduced cytokine expression of IL-1 alpha and G-CSF are noted in patients who underwent pessary placement. However, IL-6 is higher in patients with pessary relative to gestational age-matched controls. Alteration in cytokine expression following pessary placement in gravid patients is expected, however, the allergy-like response is surprising. Additionally, the reduced immune response prior to pessary placement is a novel finding.
320 Marijuana use in women with a hypertensive disorder of pregnancy: Is it safe? OBJECTIVE: Data on the association between marijuana use and pregnancy outcomes is limited. In the general population, marijuana use leads to increased blood pressure, highlighting the need to better understand the potential association between marijuana use and hypertension in pregnancy. Therefore, we assessed the relationship between marijuana use and pregnancy outcomes among women with a hypertensive disorder of pregnancy. STUDY DESIGN: Retrospective cohort study among subjects with a hypertensive disorder of pregnancy that delivered 23 weeks gestation at a single institution (October '13 e April '18). Utilizing ICD-9 and ICD-10 discharge codes, followed by individual chart review, subjects were stratified into two groups by marijuana use: current vs. non -users (never, quit prior to or during pregnancy). We assessed final hypertensive diagnosis, severe features of preeclampsia, and neonatal and maternal outcomes. Differences were analyzed by Fisher's exact, t-test, and logistic regression, with a¼0.05.
RESULTS:
From 10,833 deliveries, 1,487 (13.7%) were classified with a hypertensive disorder of pregnancy. 77 subjects (5.2%) actively used marijuana during pregnancy, 1,087 (73.1%) were non-users and 323 (21.7%) had unknown marijuana use and were excluded. Subjects using marijuana were more likely to be younger, covered by public insurance and using other substances compared to non-users (Table 1) . There were no differences in final hypertensive diagnosis for current marijuana users vs. non-users (p¼0.43), although marijuana users were more likely to experience a severe diastolic blood pressure ( 110 mmHg) compared to non-users (p¼0.014). Marijuana use was associated with adverse neonatal outcomes, which remained statistically significant when adjusting for important maternal characteristics (aOR: 1.84, p¼0.017), although this association attenuated when adjusting for other current substance use (aOR: 1.74, p¼0.081) ( Table 2) . CONCLUSION: Marijuana use was associated with adverse neonatal outcomes in women with hypertensive disorders of pregnancy.
Concomitant use of other substances was common and confounded the association between marijuana use and pregnancy outcomes. Our data highlight the need to reduce the use of marijuana as well as other substances in pregnancy.
321 Psychotropic medications do not appear to increase NAS risk in women on MAT Kathleen Lorenz, Marie Gannon, Melinda Ramage, Carol C. Coulson, Courtenay Wilson, Shelley L. Galvin
Mountain Area Health Education Center, Asheville, NC OBJECTIVE: As the incidence of neonatal abstinence syndrome (NAS) has risen, risk stratification for newborn care planning is increasingly important. Recent literature suggests concurrent in utero exposure to opioid analgesics and psychotropic medications may increase risk of NAS. We examined the association of exposure to psychotropic medications with outcomes in women with opioid use disorders using medication assisted treatment with buprenorphine (B-MAT) STUDY DESIGN: A retrospective cohort study of 115 women on B-MAT was conducted: B-MAT exposure only v. B-MAT with mental health diagnoses v. B-MAT & psychotropic medication exposure within 45 days of delivery. Primary outcomes were rates of NAS requiring treatment and positive UDS at delivery (non-prescribed substances). Secondary outcomes included gestational age at care initiation, postpartum care, newborn size, & length of stay (LOS). Chi square & Kruskal-Wallis analyses were performed (p>0.05). RESULTS: Compared to infants exposed only to B-MAT, the other cohorts had double the rates of NAS; this trend was not significant (p¼0.054; see Tables 1 & 2) . Positive UDS was not significantly different (p¼0.098). No differences were noted in newborn size or LOS. Dually diagnosed women, treated with psychotropics or not, were more likely to begin care in the first trimester; those treated with psychotropics were more likely to attend postpartum visits. CONCLUSION: Our findings are limited by sample size but suggest maternal and fetal outcomes are similar among women with concurrent opioid use disorder and mental health diagnoses whether treated with psychotropic medications or not.
